IL-6, TNF-α and IL-12p70 levels in patients with colorectal cancer and their predictive value in anti-vascular therapy
Open Access
- 26 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 997665
Abstract
We aimed to analyze the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-12 (IL-12p70) in colorectal cancer and evaluate the predictive significance of clinical efficacy of patients with colorectal cancer treated with anti-vascular therapy combined with chemotherapy. A retrospective study of 162 patients with colorectal cancer in Fujian Medical University Hospital was conducted from January 2019 to December 2020. A comparative analysis of the levels of IL-6, TNF-α and IL-12p70 between the two groups were studied. The relationship between the levels and the clinical characteristics of patients was observed; the factors affecting the levels of IL-6, TNF-α, and IL-12p70 in colorectal cancer patients were analyzed, and the predictive validity of the efficacy of anti-vascular therapy was evaluated. We observed that the individual expression levels of IL-6, TNF-α and IL-12p70 in the patients with colorectal cancer are related to lymph node metastasis, TNM staging, and degree of differentiation (P0.05). The multiple stepwise regression analysis indicates that lymph node metastasis and TNM staging are independent risk factors that correlate with IL-6 and IL-12p70 levels in colorectal cancer patients (P<0.01). The degree of differentiation was found to be an independent risk factor connected to TNF- α levels of patients with colorectal cancer. The change of IL-12p70 level could predict the validity of anti-vascular treatment for advanced colorectal cancer. When evaluated for combined expression, IL-6 and IL-12p70 in patients with colorectal cancer closely related to lymph node metastasis and TNM staging. IL-12p70 can be used as a predictor of anti-vascular therapy with colorectal cancer.Keywords
Funding Information
- Fujian Medical University
- Fujian Provincial Health Technology Project (2019-2-6)
- Medical Innovation Project of Fujian Province
This publication has 28 references indexed in Scilit:
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer Immunology, Immunotherapy, 2014
- Gene Expression of Vascular Endothelial Growth Factor A, Thymidylate Synthase, and Tissue Inhibitor of Metalloproteinase 3 in Prediction of Response to Bevacizumab Treatment in Colorectal Cancer PatientsDiseases of the Colon & Rectum, 2011
- Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non–Small Cell Lung Cancer Patients Treated with PazopanibCancer Research, 2010
- Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung CancerClinical Cancer Research, 2009
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor GrowthCancer Research, 2008
- Early destruction of tumor vasculature in tumor necrosis factor-α-based isolated limb perfusion is responsible for tumor responseAnti-Cancer Drugs, 2006
- Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other MalignanciesAnnals of Pharmacotherapy, 2004
- Chemokines in cancerCytokine & Growth Factor Reviews, 2002